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Cognitive and attentional processes governed by the prefrontal cortex (PFC) are inﬂuenced by cholinergic
innervation. Here we have explored the role of a7 nicotinic acetylcholine receptors (nAChRs) as medi-
ators of cholinergic signalling in the dorsomedial (prelimbic) PFC, using mouse brain slice electrophys-
iology. Activation of a7 nAChRs located on glutamatergic terminals and cell soma of GABAergic
interneurons increased excitation and inhibition, respectively, in layer V of the prelimbic cortex. These
actions were distinguished by their differential dependence on local acetylcholine (ACh): potentiation of
endogenous cholinergic signalling with the positive allosteric modulator, PNU-120596, enhanced
spontaneous excitatory events, an effect that was further increased by inhibition of acetylcholinesterase.
In contrast, a7 nicotinic modulation of inhibitory signalling required addition of exogenous agonist (PNU-
282987) as well as PNU-120596, and was unaffected by acetylcholinesterase inhibition. Thus a7 nAChRs
can bi-directionally regulate network activity in the prelimbic cortex, depending on the magnitude and
localisation of cholinergic signalling. This bidirectional inﬂuence is manifest in dual effects of a7 nAChRs
on theta-burst-induced long-term potentiation (LTP) in layer V of the prelimbic cortex. Antagonism of a7
nAChRs signiﬁcantly decreased LTP implicating a contribution from endogenous ACh, consistent with the
ability of local ACh to enhance glutamatergic signalling. Exogenous agonist plus potentiator also
decreased LTP, indicative of the inﬂuence of this drug combination on inhibitory signalling. Thus a7
nAChRs make a complex contribution to network activity and synaptic plasticity in the prelimbic cortex.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The prefrontal cortex (PFC) is the locus for ‘executive’ function:
cognitive processes that include working memory, attentional
processing, decision making and behavioural inhibition (Briand
et al., 2007). PFC dysfunction is implicated in many neuropsychi-
atric conditions, including schizophrenia, Alzheimer's disease,
addiction and attentional disorders (Briand et al., 2007; Lewis,
2009; Van den Oever et al., 2010). The rodent medial PFC (mPFC)
corresponds to the human dorsolateral PFC (Heidbreder and
Groenewegen, 2003). Subregions of the mPFC have been ascribed
differential roles, with the dorsomedial (prelimbic) area implicated.
r Ltd. This is an open access articlin various social, emotional and goal-directed learning (Balleine
and O'Doherty, 2010; Moorman et al., 2015). The mPFC receives
glutamatergic inputs frommany cortical and sub-cortical structures
and integration of this information results in the generation of
outputs from pyramidal neurons in layers V/VI. Glutamatergic
synapses within the mPFC can exhibit activity-dependent changes
in synaptic strength (synaptic plasticity), providing a cellular
paradigm for cognitive processes (Laroche et al., 2000). Key to
network integration within the PFC are local GABAergic in-
terneurons and it is increasingly recognised that this network is
modulated by ascending neurotransmitter systems (Briand et al.,
2007).
Cholinergic projections from the basal forebrain innervate all
layers of the mPFC (Bloem et al., 2014b) with ACh implicated in
attentional and cognitive processes (Parikh and Sarter, 2008; Bloem
et al., 2014a). The actions of ACh are mediated by multiple subtypese under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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provements in attention, working memory and executive processes
elicited by nicotine and subtype-selective nicotinic agonists has
shifted focus onto the actions of nAChRs (Wallace and Bertrand,
2013). The major nAChR subtypes, heteromeric a4b2 and homo-
meric a7 nAChRs, are expressed in the PFC and credited with pro-
cognitive properties. The non-selective agonist nicotine alters the
threshold of spike-timing dependent plasticity at glutamate syn-
apses by enhancing mPFC inhibition, an effect attributed to acti-
vation of a4b2 and a7 nAChRs on inhibitory interneurons in layers
II/III and V (Couey et al., 2007). a4b2 and a7 nAChRs are also present
on pyramidal neurons in layers VI and V respectively (Bloem et al.,
2014a) and on excitatory amino acid-releasing boutons in the PFC
(Dickinson et al., 2008).
The actions of endogenous ACh, as opposed to exogenous
agonist, are more challenging to study. However, type II positive
allosteric modulators (PAMs) of a7 nAChRs, such as PNU-120596,
allow the effects of endogenous ACh to be disclosed by prevent-
ing desensitization as well as enhancing agonist responses (Hurst
et al., 2005; Livingstone et al., 2009). In this study we have
applied PNU-120596, in the presence and absence of an a7-
selective agonist, to explore the role of a7 nAChRs in modulating
synaptic transmission in the mouse prelimbic cortex. We show that
a7 nAChRs can enhance both glutamatergic and GABAergic sig-
nalling by distinct mechanisms, giving them a bidirectional role in
prelimbic cortex neurotransmission. Endogenous ACh release
selectively targets a7 nAChRs that enhance glutamate release,
whereas global activation of a7 nAChRs by exogenous agonist was
required to enhance inhibitory signals. Through this complex in-
ﬂuence on neurotransmission a7 nAChRs can alter synaptic plas-
ticity and network function within the prelimbic cortex.
2. Materials and methods
2.1. Slice preparation
Male C57BL/6 mice, 5 weeks old and bred at the University of
Bath, were anaesthetised via intraperitoneal injection of 160 mg/kg
ketamine and 20 mg/kg xylazine and then decapitated. All mice
used were wild-type with the exception of recordings from
GABAergic interneurons where heterozygote GAD67-GFP mice
were used (Tamamaki et al., 2003). Brains were immediately
removed and submerged in ice-cold cutting solution containing in
mM: 20 NaCl, 2.5 KCl, 1.6 NaH2PO4, 7 MgCl2, 0.5 CaCl2, 60 NaHCO3,
24 D-glucose, 85 sucrose with an osmolarity of 300 mOsm/L and
saturated with 95% O2/5% CO2. Coronal brain slices (285e400 mm
thickness, 1.54e2.34 mm anterior to bregma) containing the mPFC
were obtained using a vibratome (DSK, DTK-1000). Slices were then
incubated at 32 C for 30 min in artiﬁcial cerebrospinal ﬂuid (aCSF)
containing in mM: 125 NaCl, 2.5 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 2.4
CaCl2, 21.4 NaHCO3, 11.1 D-glucose, 0.1 ascorbic acid, with an os-
molarity of 300 mOsm/L and saturated with 95% O2/5% CO2. Slices
were maintained at room temperature for at least a further 30 min
before commencing the experiment. All protocols and procedures
were in accordance with the UK Animals (Scientiﬁc Procedures) Act
1986, the European Communities Council Directive 1986 (86/609/
EEC), the ARRIVE guidelines (Kilkenny et al., 2010) and the Uni-
versity of Bath ethical review document. All efforts were made to
minimise animal suffering and to limit the number of animals used.
2.2. Whole cell patch-clamp experiments
Slices (285e300 mm) were transferred to a submerged chamber
with a continuous ﬂow rate of 2e3ml/min aCSF saturated with 95%
O2/5% CO2 at 32 C. Slices were visualised using oblique optics on anOlympus BX51WI upright microscope. Prelimbic layer V pyramidal
neurons were identiﬁed as being approximately 300e500 mm from
the slice midline and possessing a pyramidal neuron morphology.
Recording electrodes with a 2e5 MU resistance were fabricated
using a micropipette puller (Sutter-instruments, P-97). For the
Whole cell voltage clamp recordings the intracellular recording
solution contained in mM: 120 Cs methanesulphonate, 10 NaCl, 2
MgCl2, 10 HEPES, 0.5 EGTA, 5 QX314, 2 Mg-ATP, 0.25 Na-GTP, with
an osmolarity of 285 mOsm/L.
All recordings of spontaneous and miniature excitatory post-
synaptic currents (EPSCs) and inhibitory post-synaptic currents
(IPSCs) were performed in the absence of GABAergic or gluta-
matergic blockers, to ensure the continued presence of local
network activities. To achieve this, holding voltages were alter-
nated throughout the recordings from 60 mV to 0 mV (respec-
tively the reversal potentials of GABAA and AMPA receptor-
mediated currents) (Semyanov and Kullmann, 2000). At
Vh ¼ 60 mV, all spontaneous events were blocked by DNQX
(50 mM), and at Vh¼ 0mV, all spontaneous events were blocked by
picrotoxin (50 mM) (data not shown). Recordings were ampliﬁed
and ﬁltered at 2 kHz (Axopatch 200A ampliﬁer, Axon Instruments),
and digitised with a sampling rate of 10 kHz (Digidata 1440 A, Axon
Instruments). For spontaneous and miniature EPSC and IPSC ex-
periments, drugs were applied via perfusion to the slice for at least
5 min before event measurement. Miniature EPSCs and IPSCs
(mEPSC, mIPSC) were recorded in the presence of tetrodotoxin
(TTX, 1 mM). Stimulated EPSCs were evoked via a stimulus pulse
(0.05 Hz, 0.15 ms) using a metal bipolar stimulating electrode.
Stimulus intensities that gave 25e50% maximum response were
used for the entire recording. Responses were then averaged to give
an average response per minute. For all patch clamp experiments,
series resistance was measured throughout experiments and data
were excluded if series resistance changed by 25%. A liquid junction
potential of ~12 mV was calculated using pCLAMP software (Axon
instruments) and accounted for during the experiments.
For whole cell current clamp recordings of interneurons the
intracellular solution contained in mM: 120 K-gluconate, 20 KCl, 2
MgCl2, 10 HEPES, 0.2 Na-GTP, 5 Mg-ATP, with an osmolarity of
285 mOsm/L. These experiments were conducted in transgenic
GAD67-GFP C57BL/6 mice to enable ﬂuorescent identiﬁcation of
inhibitory interneurons. Cells were held at their resting membrane
potential and drugs were perfused onto the slice for at least 5 min
before membrane potential measurements. Membrane potential
measurements were taken as averaged baseline potential,
excluding any increase in voltage due to action potential discharge.
2.3. Extracellular ﬁeld recordings
Individual slices (350e400 mm) were transferred to an interface
recording chamber with a continuous ﬂow rate of 1.5e2 ml/min
aCSF saturated with 95% O2/5% CO2 at 35 C. Recording electrodes
with a 2e5 MU resistance were ﬁlled with aCSF and placed in the
layer V region of the prelimbic cortex. A bipolar metal stimulating
electrode was placed perpendicular to layer II/III of the prelimbic
cortex.
Field excitatory post synaptic potentials (fEPSPs) were evoked
via a 0.05 Hz, 0.1 ms square pulse, generated by a MASTER-8
(A.M.P.I) pulse generator and delivered via a constant current
stimulation isolation unit (DS2A, Digitimer). Stimulus intensity that
gave 50% maximum response was used for the entire recording.
fEPSPs were recorded via an Axoclamp-2A ampliﬁer (Axon In-
struments) and digitised at a sample rate of 10 kHz (CEDMicro 1401
analogue-digital converter).
For all experiments a 20 min stable fEPSP baseline was recorded
ensuring no continuous increase or decrease in response slope.
M. Udakis et al. / Neuropharmacology 105 (2016) 618e629620Long term potentiation (LTP) was induced via a high frequency
theta burst stimulation (4 bursts 10 s apart, each burst contained 7
trains 140 ms apart, each train contained 4 pulses at 100 Hz.).
2.4. Materials
Methyllycaconitine (MLA), donepezil, TTX and 6,7-
dinitroquinoxaline-2,3-dione (DNQX) were purchased from
Abcam. PNU-120596 and PNU-282987 were provided by Pﬁzer Inc.
USA. All other drugs and compounds were purchased from Sigma
Aldrich.
2.5. Data analysis
Data were acquired and analysed for both patch clamp and ﬁeld
recordings using WinEDR and WinWCP software (Strathclyde
University). fEPSP and eEPSC mean baseline was calculated by
averaging the ﬁnal 5 time points of the baseline before theta burst
stimulation or drug application, and used to normalise the data.
fEPSP and eEPSC data were excluded if baseline recordings were
unstable. For LTP data, average potentiation between 50 and 60min
post theta burst was used for statistical comparison between con-
ditions. Miniature and spontaneous EPSCs and IPSCs were detected
using a threshold of 3e7 pA and manually inspected to eliminate
false events.
Sample sizes are shown as n ¼ number of recordings (taken
from number of individual animals in parentheses). Spontaneous
and miniature EPSC and IPSC frequencies and amplitudes were
analysed via the nonparametric KolmogoroveSmirnov test (KeS
test) with p values adjusted for multiple comparisons. The same
number of events was taken for each cell so as not to skew results
towards cells with higher frequencies. Signiﬁcant differences from
control obtained via KeS test are represented as asterisks on his-
tograms and assigned when p  0.01. Excitatory to inhibitory ratios
were calculated by dividing the number of sEPSC events/min by the
number of sIPSC events/min. Differences were statistically
compared by repeated measures one-way ANOVA. All other data
were analysed via paired or unpaired Students t-tests and signiﬁ-
cance was assigned when p  0.05.
3. Results
3.1. a7 nAChRs enhance both excitatory and inhibitory signalling in
the prelimbic cortex
Initial experiments in which the selective a7 nAChR agonist
PNU-282987 (300 nM) (Hajos et al., 2005) was bath applied to
slices of mouse prefrontal cortex did not show any effect on the
frequency of spontaneous EPSCs or IPSCs recorded from layer V of
the prelimbic cortex (control vs agonist, EPSC: 472 ± 49 and
469 ± 50; IPSC: 1369 ± 178 and 1355± 166 events/min respectively,
n ¼ 5(3) p > 0.05; KeS test, Supplementary Fig. S1). The relatively
slow kinetics of bath application of drugs, combined with very
rapid agonist-induced desensitization of a7 nAChRs (Papke and
Porter Papke, 2002) could have prevented any a7 nAChR activa-
tion from occurring or being detected. To overcome this we utilised
the selective a7 nAChR type II positive allosteric modulator (PAM)
PNU-120596, which potentiates and prolongs a7 nAChR currents
(Hurst et al., 2005). PNU-120596 (10 mM) was applied in combi-
nation with PNU-282987, to investigate whether increased a7
nAChR activation modulates excitatory and inhibitory neurotrans-
mission within the prelimbic cortex. By repeatedly switching the
holding voltage of patch-clamped cells from 60 mV to 0 mV we
alternately measured the frequency of spontaneous EPSCs and
IPSCs, within the same cell (Semyanov and Kullmann, 2000), inresponse to the sequential bath application of a7 nAChR drugs.
Bath application of the a7 nAChR PAM PNU-120596 (10 mM)
alone signiﬁcantly enhanced the frequency of spontaneous EPSCs.
In contrast to expectations, when the a7 nAChR PAM PNU-120596
and the a7 nAChR agonist PNU-282987 were co-applied, the fre-
quency of spontaneous EPSCs was signiﬁcantly decreased,
compared with PAM alone (Fig. 1AeC). Subsequent application of
the a7 nAChR antagonist MLA (100 nM) had no further effect.
Measurement of spontaneous IPSCs from the same neurons
revealed substantially different effects of a7 nAChR activation on
inhibitory input. PNU-120596 alone did not signiﬁcantly alter the
frequency of spontaneous IPSCs (p ¼ 0.394; KeS test), whereas co-
application of PNU-120596 and PNU-282987 signiﬁcantly
increased the spontaneous IPSC frequency, compared with control
(p < 0.001; KeS test) and this increase was reversed on application
of MLA (100 nM) (p < 0.001; KeS test) (Fig. 1DeF).
Being able to measure the excitatory and inhibitory signalling
onto the same neuron within an intact network enables the
determination of the excitatory to inhibitory neurotransmission
ratio (E/I ratio), which highlights the overall network consequence
of a7 nAChR modulation (Semyanov and Kullmann, 2000). Upon
application of PNU-120596 alone, the E/I ratio signiﬁcantly
increased (Fig. 1G), showing an overall net increase in excitatory
neurotransmission. Upon co-application of PNU-120596 and PNU-
282987 this enhancement in the E/I ratio was signiﬁcantly
reversed (Fig. 1G) consistent with a switch from overall enhanced
excitatory drive to a predominantly inhibitory drive.
3.2. a7 nAChRs are located on GABA interneurons and glutamate
terminals
The increase in inhibitory input recorded following co-
application of a7 nAChR PAM and agonist could reﬂect increased
glutamate release onto the GABAergic interneurons. This possibility
was ruled out by the inability of the AMPA receptor antagonist
DNQX (10 mM) to prevent the increase in spontaneous IPSC fre-
quency produced by co-application of PNU-120596 and PNU-
282987. In the presence of DNQX, co-application of PNU-120596
and PNU-282987 still caused a signiﬁcant increase in sponta-
neous IPSC frequency, which was signiﬁcantly reduced by MLA
(100 nM) (Fig. 2).
Having excluded increased excitatory input as a mediator of a7
nAChR-elicited increases in inhibitory signalling, we hypothesised
that a7 nAChRs residing on the GABA interneurons themselves
were responsible. We conducted whole cell current clamp re-
cordings in layer V fast spiking and non-fast spiking inhibitory in-
terneurons in slices taken from GAD67-GFP knock-in mice to
permit visual identiﬁcation of GABAergic interneurons (Tamamaki
et al., 2003). The fast spiking and non-fast spiking inhibitory in-
terneurons were identiﬁed by their characteristic properties
(Supplementary Fig. S2), for example non-fast spiking interneurons
displayed a lower frequency of action potentials following current
injection compared with fast spiking interneurons (Fig. 3A).
Application of PAM alone onto 8 interneurons from 3 GAD67-GFP
mice revealed no depolarisation of either cell type (Fig. 3B, C). In
contrast we observed a signiﬁcant depolarisation of non-fast
spiking, but not fast spiking, interneurons in response to co-
application of PNU-120596 and PNU-282987, and this was
blocked by MLA (Fig. 3B, D). In the majority of non-fast spiking
neurons, this depolarisation was sufﬁcient to induce action po-
tential discharge (see Fig. 3B), and provides evidence that a7
nAChRs residing on cell bodies of non-fast spiking inhibitory in-
terneurons can directly alter the levels of inhibitory signaling
within the prelimbic cortex.
To determine whether a7 nAChRs are located on nerve
Fig. 1. a7 nAChR activation differentially regulates excitatory and inhibitory signalling in the prelimbic cortex. Spontaneous EPSCs (sEPSCs) and IPSCs (sIPSCs) were recorded from
the same layer V pyramidal neurons of the prelimbic cortex by switching the holding voltage between 60 mV and 0 mV respectively (see Methods). The a7 nAChR-selective PAM
PNU-120596 (10 mM) alone, followed by PAM plus a7 nAChR-selective agonist PNU-282987 (300 nM) were bath applied, before addition of 100 nM MLA. A,D. Cumulative inter-
event interval distribution of sEPSCs (A) and sIPSCs (D) in the presence and absence of different drug combinations. B,E. example traces of spontaneous events. C,F. summary of
sEPSC (C) and sIPSC (F) frequencies * signiﬁcantly different, p  0.001, KeS test based on corresponding cumulative frequency plots n ¼ 7 (4). G. Excitatory/inhibitory (E/I)
transmission ratio * signiﬁcantly different, p  0.05, ** signiﬁcantly different, p  0.01: one-way repeated measures ANOVAwith Dunnett's post hoc test, n ¼ 7 (4). Scale bars: 30 pA
and 0.5 s.
Fig. 2. a7 nAChR-induced increase in spontaneous IPSC frequency is independent of glutamate signalling. Spontaneous IPSCs (sIPSCs) were recorded in the presence of the AMPA
receptor antagonist DNQX. A. Cumulative inter-event interval distributions, showing the change in sIPSC frequency in the presence of DNQX (10 mM) after bath application of a7
nAChR PAM (PNU-120596; 10 mM) alone and with a7 nAChR agonist (PNU-282987; 300 nM), in the absence then presence of 100 nM MLA. B. Summary histogram of sIPSC
frequencies.* Signiﬁcantly different, p  0.001, KeS test based on cumulative frequency plots shown in A; n ¼ 6 (4).
M. Udakis et al. / Neuropharmacology 105 (2016) 618e629 621terminals of GABAergic interneurons, miniature IPSCs were recor-
ded from layer V pyramidal neurons, in the presence of tetrodo-
toxin (1 mM). PNU-120596 alone and co-application of PNU-120596
with PNU-282987 failed to alter either the frequency or amplitudeof miniature IPSCs (Fig. 4A, B). This result provides no evidence for
presynaptic a7 nAChRs on mPFC interneurons, and we conclude
that a7 nAChRs are located on the cell bodies (of fast-spiking in-
terneurons) but not nerve terminals of interneurons, in agreement
Fig. 3. a7 nAChR activation but not positive allosteric modulation directly depolarises
layer V inhibitory interneurons. Changes in the membrane potential of layer V non-fast
spiking (NFS) and fast spiking (FS) inhibitory interneurons were recorded in response
to a7 nAChR modulation activation and inhibition. A. Spiking proﬁle of layer V NFS
(left) and FS (right) interneurons in response to a 300 ms current injection of þ150 pA
or 150 pA. Scale bars 50 mV and 100 ms. B. Representative current clamp recording
from NFS (left) and FS (right) showing the changes in membrane potential in response
to 10 mM PNU-120596 (‘PNU 1’), co-application of PNU-120596 and 300 nMPNU-
282987 (‘PNU1 þ PNU 2’), and addition of 100 nM MLA. C. Averaged membrane po-
tential in response to 10 mM PNU-120596 in NFS (left; n ¼ 3) and FS (right; n ¼ 5)
interneurons; recordings from 3 animals (C), and in response to co-application of PNU-
120596 and 300 nM PNU-282987 followed by addition of 100 nM MLA in NFS (left;
n ¼ 5) and FS (right; n ¼ 5); recordings from 3 animals (D). * signiﬁcantly different
from control, p  0.05, one-way repeated measures ANOVA with Dunnett's post hoc
test.
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Poorthuis et al., 2012), and see Fig. 3.
When interneuron action potential ﬁring was abolished by the
use of tetrodotoxin a7 nAChR activation no longer affected inhibi-
tory input. This strategy enabled us to observe the effects of pre-
synaptic a7 nAChRs on excitatory transmission in isolation. Incontrast tominiature IPSCs, application of the a7 nAChR PAM (PNU-
120596) signiﬁcantly increased miniature EPSC frequency (Fig. 4C)
with no effect on miniature EPSC amplitude (8.3 ± 0.4 to
7.9 ± 0.31 pA, n¼ 11 (9) p > 0.05; KeS test). These data suggest that
a7 nAChRs are located on nerve terminals of afferent glutamatergic
inputs.
Co-application of PNU-120596 (10 mM) and PNU-282987
(300 nM) in the presence of TTX resulted in a substantial ﬂuctua-
tion of membrane current in recorded cells (Supplementary
Fig. S3), presumably due to high levels of a7 nAChR-driven gluta-
matergic input in the absence of inhibitory modulation. Application
of a lower (submaximal) concentration of PNU-282987 (30 nM)
together with PNU-120596 (10 mM) produced stable recordings
that revealed a signiﬁcant increase in the frequency of miniature
EPSCs (Fig. 4D) with no change in miniature EPSC amplitude
(8.3 ± 0.6 to 8.0 ± 0.3 pA, n ¼ 3 (3) p > 0.05; KeS test). Together
these data suggest that exogenous activation of a7 nAChRs with
PNU-282982 and PNU-120596 is capable of enhancing presynaptic
glutamate release, but this effect is attenuated via a7 nAChR acti-
vation of inhibitory interneurons in a functionally intact network as
observed in spontaneous EPSCs (Fig. 1A-C).3.3. Acetylcholinesterase inhibition enhances PNU-120596-induced
increases in EPSCs
The bidirectional effect of a7 nAChR activation on layer V py-
ramidal neurons of the prelimbic cortex reﬂects activation of all of
the a7 nAChRs within the slice, through the combined action of a
selective a7 nAChR agonist and PAM, leading to an increase in
inhibitory drive onto layer V pyramidal neurons, whereas applica-
tion of the a7 nAChR PAM alone selectively enhances excitatory
drive onto layer V neurons. This difference could reﬂect a different
spatial or temporal relationship between cholinergic afferents and
glutamatergic nerve terminals, such that local ACh preferentially
targets presynaptic a7 nAChRs that modulate glutamate release,
rather than a7 nAChRs on the cell bodies of GABAergic
interneurons.
To test this hypothesis we further enhanced the levels of
endogenous ACh by preventing its enzymatic breakdown, using the
acetylcholinesterase inhibitor donepezil. Donepezil alone (10 mM)
did not signiﬁcantly alter the frequency of spontaneous EPSCs or
IPSCs (Fig. 5A). However, in the presence of the a7 nAChR PAM
PNU-120596 (10 mM), donepezil signiﬁcantly increased the spon-
taneous EPSC frequency, compared to both control and to PNU-
120596 alone (Fig. 5B). This enhancement was reversed by MLA
(100 nM). In contrast, donepezil did not alter the spontaneous IPSC
frequency, with or without PNU-120596 (Fig. 5C). These data sup-
port the hypothesis that endogenous ACh release targets a7 nAChRs
that selectively enhance excitatory neurotransmission, and not
inhibitory neurotransmission, in layer V of the prelimbic cortex.
MLA was also applied alone to investigate the level of tonic
background receptor activation. In these experiments MLA alone
caused a slight overall decrease in sEPSC frequency. A clear decrease
in frequency was seen in 3 out of 6 neurons (Overall: 313 ± 34
(control) to 275 ± 34 (þMLA) events/min, n ¼ 6 (4) p ¼ 0.04; KeS
test). No effect of MLA was seen on sIPSC frequency (691 ± 99 to
714 ± 97 events/min, n ¼ 6(4) p ¼ 0.85; KeS test) (Supplementary
Fig. S4). This is consistent with the hypothesis that tonic ACh
preferentially activates a7 nAChRs on glutamatergic nerve termi-
nals, although the magnitude of effect of MLA was less than that
seen when a7 nAChRs were further activated with the a7 PAM.
Fig. 4. Effect of a7 nAChR activation on miniature EPSCs and IPSCs. Miniature IPSC (mIPSC) and EPSC (mEPSC) frequencies were measured in layer V pyramidal neurons of the
prelimbic cortex in the presence of tetrodotoxin (1 mM) to block axonal conduction. Cumulative distribution and summary histograms (inserts) of mIPSC (A,B) and mEPSC (C,D)
frequencies in the presence or absence of PNU-120596 (10 mM) alone (‘PNU 1’; n ¼ 11 (9)) (A,C) or PNU-120596 (10 mM) co-applied with PNU-282987 (300 nM) (‘PNU 1 þ PNU 2’;
n ¼ 5 (4)) (B), or PNU-282987 (30 nM) (‘PNU 1 þ PNU 2’; n ¼ 3 (3)) (D). Representative traces are shown beneath each panel. * signiﬁcantly different from control, p  0.001, KeS
test based on corresponding cumulative frequency plot. Scale bars: 30 pA and 0.5 s.
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glutamate release
To further investigate the role of a7 nAChRs in excitation within
the prelimbic cortex we examined the receptors’ role in modulating
evoked neurotransmitter release. Electrically stimulating layers II/
III of the prelimbic cortex and recording from pyramidal neurons in
layer V held at60 mV, in the absence of GABAA receptor blockade,
resulted in a DNQX-sensitive glutamatergic response. Upon pro-
longed bath application of the a7 nAChR antagonist MLA (100 nM),
the amplitudes of evoked EPSCs signiﬁcantly decreased (Fig. 6A).Similarly, co-application of a7 nAChR PAM PNU-120596 (10 mM)
and a7 nAChR agonist PNU-282987 (300 nM) also signiﬁcantly
reduced evoked EPSC amplitudes (Fig. 6B). However, application of
PNU-120596 alone failed to alter evoked EPSC amplitudes (Fig. 6C).
The quantitative difference of the effect of PAM on spontaneous and
evoked glutamate responses could reﬂect their differential modu-
lation by a7 nAChRs.
3.5. a7 nAChRs modulate LTP in the prelimbic cortex
The evidence for the bidirectional control that a7 nAChRs exert
Fig. 5. Enhancing endogenous acetylcholine selectively potentiates excitatory signalling. Spontaneous EPSCs (sEPSCs) and IPSCs (sIPSCs) were recorded from layer V pyramidal
neurons in the presence and absence of donepezil (10 mM) to block acetylcholinesterase activity. A. Cumulative inter-event interval distributions and summary histogram of sEPSC
and sIPSC frequencies conﬁrm that donepezil had no effect on either sEPSC or sIPSC frequency; n ¼ 8 (5). B,C Cumulative inter-event interval distributions and summary histogram
of sEPSCs (B) and sIPSCs (C) in the presence and absence of PNU-120596 (10 mM), donepezil (10 mM), and MLA (100 nM), n ¼ 6 (6). * signiﬁcantly different, p  0.001, KeS test based
on corresponding cumulative frequency plot.
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to affect pronounced glutamate release, suggests that a7 nAChRs
could also play a role in modulating more complex network ac-
tivity. To explore this possibility, we assessed the ability of a7
nAChRmodulation to inﬂuence long term potentiation (LTP) within
the prelimbic cortex.
Extracellular ﬁeld recordings were conducted to measure the
level of theta burst-induced LTP in the presence of different a7
nAChR ligands, to promote or inhibit a7 nAChR activity. Firstly, MLA
was used to reveal any intrinsic a7 nAChR contribution arising from
endogenous ACh. In this case MLAwas predicted to reduce the level
of LTP by decreasing a7 nAChR-enhanced glutamate signaling.
Indeed, application of MLA (100 nM) 10 min before and during a
theta burst stimulation produced a signiﬁcant reduction in the level
of LTP (Fig. 7A). Conﬁrmation that this was a7 nAChR-mediated was
provided by the pseudo-irreversible a7 nAChR antagonist a-bun-
garotoxin (a-BGT; 300 nM), which produced a comparable decreasein LTP (control: 165 ± 19% baseline, n ¼ 4 (4), a-BGT: 120 ± 5%
baseline, n ¼ 5 (5); p < 0.05; t-test 60 min post theta-burst;
Supplementary Fig. S5.)
Combined application of both PAM (PNU-120596; 10 mM) and
agonist (PNU-282987; 300 nM), 20 min before and during a theta
burst stimulation also resulted in a signiﬁcant reduction in the level
of LTP (Fig. 7B). This is consistent with an enhancement of inhibi-
tory signaling, as seen in the measurements of spontaneous IPSCs
and the reduction in evoked glutamate in response to a7 nAChR
PAM and agonist application.
In view of the inability of a7 nAChR PAM alone to alter the levels
of evoked glutamate (Fig. 6C), we predicted that positive allosteric
modulation of the a7 nAChR should not alter the levels of theta
burst LTP. Indeed, we found that LTP recorded in the presence of
PNU-120596 (10 mM) was indistinguishable from that in control
slices (Fig. 7C).
Fig. 6. Both antagonism and activation of a7 nAChRs decreases evoked EPSC ampli-
tudes. EPSCs were evoked in layer V pyramidal neurons by stimulation of distal den-
drites in layers II/III of the prelimbic cortex. The amplitude of these EPSCs was
measured before and after bath application of (A) MLA (100 nM), n ¼ 4 (4), (B) co-
application of the a7 nAChR PAM PNU-120596; (10 mM) and a7 nAChR agonist PNU-
282987 (300 nM), n ¼ 5 (5), and (C) a7 nAChR 10 mM PAM alone, n ¼ 4 (4). Time-
courses show amplitude of evoked potentials as a % of mean control potentials that
were collected for 20 min in the absence of drugs; histograms show averaged data at
time points 10 min (control) and 40 min (drug). * signiﬁcantly different from control,
p  0.05, paired t-test.
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We show that a7 nAChRs play a complex bidirectional role in
mediating network excitability in the prelimbic cortex. Enhancing
cholinergic tone with the a7 nAChR PAM PNU-120596 increases
overall excitation whereas global activation of a7 nAChRs with a
combination of agonist (PNU-282987) and PAM enhances overall
inhibition. Both global activation (by PAM and agonist) and inhi-
bition (by the a7 nAChR antagonist MLA) of a7 nAChRs inhibited
induction of theta-burst-induced LTP in the prelimbic cortex,
reﬂecting the differential effects of a7 nAChRs on excitation and
inhibition.4.1. Bi-directional effects of a7 nAChR activation
It is well recognised that a7 nAChRs can regulate both excitatory
and inhibitory signalling in the brain (Griguoli and Cherubini, 2012;
Yakel, 2013; Hedrick and Waters, 2015). In the PFC, layer Vpyramidal neurons are excited by nAChRs that enhance gluta-
matergic inputs (hitherto attributed to b2* nAChRs (Lambe et al.,
2003)) and nAChRs also increase inhibition to layer V pyramidal
neurons (Couey et al., 2007). Recording spontaneous PSCs alter-
nately at 0 mV and 60 mV (corresponding to the estimated
reversal potentials of ionotropic glutamate and GABAA receptors,
respectively (Semyanov and Kullmann, 2000)) enabled the
recording of inhibitory and excitatory events in the same cell,
without pharmacological blockade of the preparation. This has
revealed that individual layer V pyramidal neurons are subject to
excitatory and inhibitory inputs that are both enhanced by a7
nAChRs. By avoiding the need for blockers of GABAA or glutamate
receptors, the net effect of a7 nAChRs’ modulatory inﬂuences on
evoked responses and synaptic plasticity could be evaluated.
The ability of a7 nAChR-selective PAM plus agonist to depolarise
inhibitory interneurons and increase spontaneous IPSCs, in a TTX-
sensitive and DNQX-independent manner, is consistent with the
well documented evidence for somatic a7 nAChRs on GABAergic
interneurons in the PFC (Couey et al., 2007; Aracri et al., 2010). We
show that within the prelimbic layer V, non-fast spiking inhibitory
interneurons undergo a more pronounced depolarisation to a7
nAChR activation compared to fast spiking interneurons. This could
be attributed to the differential expression of a7 nAChRs on
different interneuron subtypes throughout cortical layers as pre-
viously shown (Poorthuis et al., 2012). In addition to functional
studies, immunoreactivity attributed to a7 nAChRs has been
localised to GABAergic dendritic shafts and somata in guinea pig
medial PFC (Lubin et al., 1999) providing some ultrastructural evi-
dence for this association.
In contrast, a7 nAChRs on glutamatergic boutons in the pre-
limbic cortex are inferred from the ability of the a7 nAChR PAM
PNU-120596 to enhance spontaneous EPSC frequency in a manner
that was insensitive to TTX, as seen by the PAM-induced increase in
miniature EPSCs (Fig. 4). There is functional and ultrastructural
evidence for presynaptic a7 nAChRs on hippocampal mossy ﬁbre
terminals (Gray et al., 1996; Sharma et al., 2008; Cheng and Yakel,
2014) and glutamatergic inputs to the ventral tegmental area
(Jones and Wonnacott, 2004; Good and Lupica, 2009; Garzon et al.,
2013). Evidence for presynaptic a7 nAChRs in the PFC is limited:
local infusion of an a7 nAChR agonists into the rat PFC have been
shown to transiently increased glutamate release (Konradsson-
Geuken et al., 2009; Bortz et al., 2013), consistent with the
demonstration of functional a7 nAChRs on excitatory amino acid
nerve terminals (Dickinson et al., 2008).
Nicotine or ACh provokes a large excitation of layer V pyramidal
neurons in the PFC, but this has previously been attributed to a4b2*
nAChRs on thalamo-cortical terminals (Lambe et al., 2003; Couey
et al., 2007; Poorthuis et al., 2013). In the present study we spe-
ciﬁcally examined a7 nAChRs by utilising subtype-selective phar-
macological tools. This approach has revealed a presynaptic action
of a7 nAChRs that may have been either masked, in the presence of
a larger a4b2* nAChR-mediated response, or absent due to desen-
sitization in previous studies. The ability of MLA to inhibit theta-
burst stimulated LTP (Fig. 7) argues for a7 nAChRs making a
physiological contribution to overall activity in the PFC. Interest-
ingly, we saw no somatic currents induced by a7 nAChRs in layer V
pyramidal cells, unlike some previous reports (Poorthuis et al.,
2013), but see (Hedrick and Waters, 2015).
4.2. Cholinergic signalling mediated by a7 nAChRs in the prelimbic
cortex
The a7 nAChR PAM PNU-120596, applied in the absence and
presence of exogenous agonist, revealed the contribution of
endogenous ACh to excitatory, but not inhibitory, signalling. The
Fig. 7. Both antagonism and activation of a7 nAChRs inhibit long-term potentiation in layer V of the prelimbic cortex. Field EPSPs (fEPSPs) were recorded from prelimbic layer V;
long-term potentiation was induced via a theta burst stimulation in layer II/III. Recordings were made in the absence (control n ¼ 7 (7)) and presence of bath applied MLA (100 nM;
n ¼ 5 (5)) (A), a7 nAChR PAM PNU-120596 (10 mM) and agonist PNU-282987 (300 nM) (control; n ¼ 6 (6); drug n ¼ 5 (5)) (B), and 10 mM PNU-120596 alone (control n ¼ 6 (6); drug
n ¼ 5 (5) (C). MLA and PNU-120596 were bath applied for 10 min before and during theta-burst stimulation whereas PNU-120596 þ PNU-282987 co-application was bath applied
for 20 min. Histogram (right) shows % LTP potentiation from baseline taken 50e60 min post theta burst for each slice. Both MLA and co-application of PNU-120596 and PNU-282987
signiﬁcantly reduced the levels of LTP from control, p  0.05, t-test.
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frequency, and additional enhancement by the AChE inhibitor
donepezil corroborates a role for endogenous ACh in modulating
glutamate release. Choline, the breakdown product of ACh when
metabolised by AChE, is also an a7 nAChR agonist (Alkondon et al.,
1997; Innocent et al., 2008). Our ﬁndings with donepezil, however,
indicate that the endogenous a7 nAChR activation observed is via
ACh, not choline.
The efﬁcacy of the PAM alone in increasing EPSCs suggests that,
in the slice, sufﬁcient ACh persists in the vicinity of glutamatergic
boutons to activate a7 nAChRs when the receptors are sensitised by
the PAM; this may signify a local, tonic release of ACh. In contrast
the inability of the PAM alone, but the requirement for both PAM
and agonist, to elicit a depolarisation of inhibitory interneurons and
an increase in layer V pyramidal neuron IPSCs suggests that
inhibitory neurons are subject to a distinct mode of cholinergic
signalling. This may rely on activity-dependent ACh release from apopulation of cholinergic ﬁbres that form direct synaptic connec-
tions with a7 nAChR-expressing inhibitory interneurons (Bennett
et al., 2012). Alternatively, it could reﬂect a different spatial rela-
tionship such that tonically released ACh is insufﬁciently available
to a7 nAChRs on GABAergic interneurons (Fig. 8). We cannot
presently distinguish between these possibilities. Cholinergic
innervation from the basal forebrain is widely distributed through
the cortical layers, apart from layer IV where it is less dense (Aracri
et al., 2010; Bloem et al., 2014b). Projections from the basal fore-
brain are physiologically heterogeneous, with respect to conduc-
tion velocity and spontaneous activity (Aston-Jones et al., 1985),
and the predominant varicose pattern of innervation is consistent
with a paracrine delivery of ACh (Duffy et al., 2009; Aracri et al.,
2010). In addition, sparse, intrinsic cholinergic interneurons are
also present in the cortex, but these predominate in layers 2 and 3
(Engelhardt et al., 2007).
Interestingly, although there was sufﬁcient basal cholinergic
Fig. 8. Layer V pyramidal neurons are dynamically controlled by a7 nAChRs. A model
illustrating the potential locations of a7 nAChRs and the interplay between gluta-
matergic, GABAergic and cholinergic systems in layer V of the prelimbic cortex. a7
nAChRs are shown on the terminal of a glutamatergic afferent (green) and on cell
bodies of inhibitory interneurons (yellow). Thus a7 nAChRs are able to inﬂuence both
the excitability and inhibition of layer V pyramidal neurons (blue). Tonic endogenous
ACh selectively targets a7 nAChRs on glutamatergic terminals, suggesting close
proximity to tonically active en passant varicosities (orange). In contrast, GABAergic
interneurons bearing a7 nAChRs are either more distant from cholinergic ﬁbres, or
localised close to tonically inactive varicosities (brown). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.).
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midal cells, this effect was attenuated by co-administration of PAM
and agonist (Fig. 1AeC). This suggests that GABAergic interneurons
may provide inhibitory input to glutamatergic terminals (Fig. 8),
such that global activation of a7 nAChRs can overcome the direct
excitatory effect of a7 nAChRs on glutamatergic terminals.
This ﬁnding is consistent with the reduced levels of evoked
EPSCs observed in response to co-administration of the a7 PAM
plus agonist (Fig. 6B). Surprisingly, evoked glutamate levels were
not enhanced upon a7 PAM administration alone. This ﬁnding may
be explained by the relative levels of glutamate and ACh released
under evoked versus basal conditions. Evoked release would be
expected to elevate cholinergic tone that may produce a near
maximal effect at glutamatergic nerve terminals, limiting any
potentiation with a PAM. If this is correct then with elevated levels
of ACh during evoked experiments we would expect to be able to
inhibit its effect with MLA, as seen in Fig. 6A. Whereas with lower
tonic levels of ACh during spontaneous experiments we might
expect not to see a pronounced reduction in glutamate release as
seen by only a modest reduction in spontaneous glutamate release
upon MLA application (Supplementary Fig. S4).
4.3. Roles of a7 nAChRs in integrating network activity
The PFC in general, including the prelimbic cortex, has attracted
considerable attention because of its importance for executive
function and attentional processes. a7 nAChRs in this brain region
have been studied as a possible novel target for cognitive and
executive-control disorders such as schizophrenia, Alzheimer'sdisease, attention-deﬁcit hyperactivity disorder and addiction
states (Pandya and Yakel, 2013; Poorthuis and Mansvelder, 2013;
Wallace and Bertrand, 2013). Our ﬁnding that a7 nAChRs play a
bidirectional role in network activity in the prelimbic cortex point
to a more complex function for a7 nAChRs in this brain region than
previously recognised.
The differential effects of PAM and agonist on excitatory and
inhibitory signalling provides a means of discriminating their
contributions to network activity manifest in evoked responses and
synaptic plasticity. Synaptic plasticity is widely recognised as a
neuronal correlate of learning and memory, and a7 nAChRs have
been shown to modulate synaptic plasticity. This has been most
extensively studied in the hippocampus, where activation of a7
nAChRs enhances LTP induction (Welsby et al., 2006; Lagostena
et al., 2008) and LTP induction is attenuated in a7 nAChR
knockout mice, or by a7 nAChR antagonists (Welsby et al., 2006; Gu
and Yakel, 2011). The dual action of a7 nAChRs on plasticity in the
prelimbic cortex also resonate with similar mechanisms in the
hippocampus (Ji et al., 2001; Gu and Yakel, 2011). Interestingly, the
enhancing effect of the a7 nAChR partial agonist, S 24795, on hip-
pocampal LTP was only seen at lower concentrations; higher con-
centrations reduced LTP induction (Lagostena et al., 2008). We see
similar biphasic actions of a7 nAChRs, depending on the level of
receptor activation, on LTP in the prelimbic cortex (Fig. 7). These
data provide evidence that a7 nAChRs enhance LTP is via actions at
glutamatergic nerve terminals, whereas their inhibitory effect on
LTP is via actions at GABAergic interneurons. Previous studies have
also shown that nAChRs on inhibitory interneurons inﬂuence
spike-timing dependent plasticity in the mPFC (Couey et al., 2007).
However, these ﬁndings were largely attributed to heteromeric
nAChRs whereas the present study reveals that homomeric a7
nAChRs can similarly alter plasticity. Complementary roles for b2-
containing and a7 nAChRs have also been reported with respect
to the modulation of network activity in mouse barrel cortex
(Sigalas et al., 2015).
Within the mPFC network, multiple nicotinic and muscarinic
AChRs are expressed on distinct network components across
multiple cortical layers (Vidal and Changeux, 1993; Poorthuis et al.,
2012), suggesting individual ACh receptor subtypes may have
complex roles in regulating the cortical network (Parikh et al.,
2010). This focussed pharmacological study highlights a new
complexity in how a7 nAChRs within this system can bidirection-
ally inﬂuence network activity. They may complement heteromeric
nAChRs by differences in subcellular localisation: preterminal a4b2
nAChRs have been inferred on thalamocortical glutamatergic in-
puts (Lambe et al., 2003), whereas the present studies indicate that
a7 nAChRs reside on nerve terminals of glutamatergic inputs.
In addition to differences in spatial expression of multiple ACh
receptor subtypes, the different modes of ACh release are increas-
ingly recognised as critical regulators of attentional processes
(Sarter et al., 2009). We show that tonic ACh release, acting through
a7 nAChRs, can directly modulate excitation whilst elevated ACh
signalling activates a7 nAChRs to regulate inhibitory interneuron
activity. Understanding how ACh orchestrates network activity
through these nAChRs will be critical to understanding the role of
ACh in mediating cognitive processes (Bloem et al., 2014a). Our
ﬁndings suggest that a7 and a4b2 receptors need to be considered
together to better understand the functional consequences of ACh
release in the mPFC.
In conclusion, we demonstrate that a7 nAChRs in the prelimbic
region of the mouse prefrontal cortex exert a bidirectional effect on
network excitability. Basal cholinergic tone preferentially activates
a7 nAChRs located on glutamatergic nerve terminals and has an
overall excitatory effect on pyramidal output cells, whereas global
activation of a7 nAChRs leads to enhanced GABAergic input to both
M. Udakis et al. / Neuropharmacology 105 (2016) 618e629628pyramidal cells and glutamatergic nerve terminals. These effects
result in the seemingly contradictory ﬁnding that both inhibition
and global activation of a7 nAChRs can inhibit LTP induction in this
brain region. a7 nAChRs have attracted interest as potential ther-
apeutic targets for cognitive and attentional disorders such as
schizophrenia, Alzheimer's disease and autism (Bertrand et al.,
2015). Our ﬁndings indicate that differences in the manner and
extent by which a7 nAChRs are activated can have different func-
tional and physiological consequences, and highlights the challenge
for designing effective drug treatments targeted at a7 nAChRs.
5. Conclusions
The prelimbic cortex plays a key role in attention, executive
control and decision-making. Outputs reﬂect the balance of excit-
atory and inhibitory systems, which are modulated by transmitters
like acetylcholine. We investigated how the contributions of
acetylcholine acting at a7 nicotinic acetylcholine receptors
(nAChRs) alter activity in the prelimbic cortex. Activation of a7
nAChRs increased both excitatory and inhibitory signaling, but with
differing sensitivities to acetylcholine. Enhancing available acetyl-
choline results in overall excitation, whereas global activation of a7
nAChRs with an exogenous agonist results in overall inhibition.
These ﬁndings are mirrored by effects on synaptic plasticity, where
both antagonism and global activation of a7 nAChRs decrease long-
term potentiation, highlighting a complex bidirectional role for a7
nAChRs in the prelimbic cortex.
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